Gary Shapiro, PhD

Watertown, United States
Gary Shapiro, PhD., Vice President of Discovery Biology at Affini-T Therapeutics, is an immunologist with extensive oncology and cell therapy experience dedicated to making a dramatic difference in patients’ lives through creative, rigorous, and transformative science. Previously, Gary built and led the Cell Therapy Discovery Team at Takeda Oncology, where he drove the internal portfolio from project conception through clinical entry as well as directed external collaborations with academic and industry partners. Prior to joining Takeda in 2017, Gary spent 7 years at Sanofi leading a Target Identification group exploring biologics and small molecules targeting genetic drivers of cancer and served as the global project lead for their TGFβ ligand trap that was investigated in a Phase 1 solid tumor trial. Gary’s training includes both immunology (National Jewish Hospital/University of Colorado) and oncology (University of California San Diego/HHMI).
Speaking In
4:00 PM - 4:15 PM
Wednesday, June 7
Affini-T is unlocking the power of T cells and targeting core oncogenic drivers to develop…
Session Room 104B